Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 2Not yet recruiting 2Suspended 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, Non-Hodgkin 10Lymphoma 10Lymphoma, Mantle-Cell 7Recurrence 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Neoplasms 4Leukemia, B-Cell 3Neoplasm, Residual 2Burkitt Lymphoma 2Mature B-Cell Malignancies 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 9Magnetic Resonance Spectroscopy 8Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6polatuzumab vedotin 5obinutuzumab 5Biopsy 5zanubrutinib 4glofitamab 4Nivolumab 4Etoposide 4Dexamethasone 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Leukapheresis 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2loncastuximab tesirine 2etoposide phosphate 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × obinutuzumab × 90 days × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Nurix Therapeutics, Inc.

Phase 1/2 Not yet recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06824701 2026-04-06

TARZAN

University of Utah

Phase 1 Suspended
24 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT07502872 2026-03-31

TPG

Brown University

Phase 2 Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡